Novel agents and regimens in acute myeloid leukemia: latest updates from 2022 ASH Annual Meeting

Novel agents and regimens in acute myeloid leukemia: latest updates from 2022 ASH Annual Meeting

Abstract Developments in investigational agents and novel regimens in acute myeloid leukemia (AML) were reported in the 2022 American Society of Hematology (ASH) annual meeting. Encouraging efficacy data were presented from first-in-human studies of two investigational menin inhibitors, SNDX-5613 an...

Full description

Bibliographic Details
Main Authors: Katherine W. DiNardo, Thomas W. LeBlanc, Hui Chen
Format: Article
Language:English
Published: BMC 2023-03-01
Series:Journal of Hematology & Oncology
Subjects:
Acute myeloid leukemia
AML
Investigational therapies
Clinical research
Online Access:https://doi.org/10.1186/s13045-023-01411-x

Similar Items

Similar Items